New Oral Pharmaceutical Composition And Dose Regimen For The Therapy Of Progressive Fibrosing Interstitial Lung Diseases
Patent No. EP4426307 (titled "New Oral Pharmaceutical Composition And Dose Regimen For The Therapy Of Progressive Fibrosing Interstitial Lung Diseases") was filed by Boehringer Ingelheim on Dec 8, 2022. The application was issued on Jul 2, 2025.
Patent Summary
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4426307
- Application Number
- EP22835249A
- Filing Date
- Dec 8, 2022
- Status
- Granted And Under Opposition
- May 29, 2025
- Publication Date
- Jul 2, 2025
- External Links
- Slate, Register , Google Patents